Glucocorticoids in the treatment of children with acute lymphoblastic leukemia and Hodgkin's disease: A pilot study on the adverse psychological reactions and possible associations with neurobiological, endocrine, and genetic markers

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7093-7100

  Felder Puig, Rosemarie ^a   Scherzer, Christiane ^a   Baumgartner, Michaela ^a   Ortner, Magdalena ^a   Aschenbrenner, Claudia ^a   Bieglmayer, Christian ^b   Voigtländer, Till ^b   Panzer Grümayer, E Renate ^c   Tissing, Wim J E ^d,f   Koper, Jan W ^e   Steinberger, Karl ^a   Nasel, Christian ^b   Gadner, Helmut ^a   Topf, Reinhard ^a   Dworzak, Michael ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b Medical University   (Austria)

^c CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BIOLOGICAL MARKER; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLIC ACID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PRASTERONE SULFATE; PREDNISOLONE; PROCARBAZINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANXIETY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL DESTRUCTION; CEREBROSPINAL FLUID; CHILD; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEPRESSION; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; ENDOCRINE SYSTEM; FEEDING BEHAVIOR; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE RELEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NERVE CELL; NEUROBIOLOGY; PARENT; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGY; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THOUGHT DISORDER; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; CELL DEATH; CHILD; CHILD BEHAVIOR; CHILD, PRESCHOOL; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCRINE SYSTEM; FEEDING BEHAVIOR; FEMALE; GLUCOCORTICOIDS; HODGKIN DISEASE; HORMONES; HUMANS; MALE; MENTAL DISORDERS; NEURONS; PILOT PROJECTS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; PROSPECTIVE STUDIES; RECEPTORS, GLUCOCORTICOID;

EID: 37249083924     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0902     Document Type: Article

References (49)

1. Langebrake C, Reinhardt D, Ritter J. Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf 2002;25:1057-77.
2. Belgaumi AF, Al-Bakrah M, Al-Mahr M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 2003;98:2898-903.
3. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisolone and daily oral versus weekly intravenous mercaptopurine for patients with standard risk acute lymphoblastic leukaemia. Blood 2003;101:3809-17.
4. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-45.
5. Stuart FA, Segal TY, Keady S. Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child 2005;90:500-6.
6. Goodyer IM, Herbert J, Tamplin A, et al. Recent life events, cortisol, dehydroepiandrosterone and the onset of major depression in high-risk adolescents. Br J Psychiatry 2000;177:499-504.
7. Goodyer IM, Park RJ, Netherton CM, Herbert J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. Br J Psychiatr 2001;179:243-9.
8. Korte SM, Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev 2001;25:117-42.
9. Kaufman J, Birmaher B, Perel J, et al. The corticotrophin-releasing hormone challenge in depressed abused, depressed nonabused, and normal control children. Biol Psychiatry 1997;42:669-79.
10. van Eck M, Berkhof H, Nicolson N, et al. The effects of perceived stress, traits, mood states, and stressful daily events on salivary cortisol. Psychosom Med 1996;58:447-58.
11. Rao U, Dahl RE, Ryan ND, et al. The relationship between longitudinal clinical course and sleep and cortisol changes in adolescent depression. Biol Psychiatry 1996;40:474-84.
12. Uno H, Eisele S, Sakai A, et al. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav 1994;28:336-48.
13. Sapolsky RM, Uno H, Rebert CS, et al. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 1990;10:2897-902.
14. Ohl F, Michaelis T, Vollmann-Honsdorf GK, et al. Effect of chronic psychosocial stress and long-term cortisol treatment on hippocampus-mediated memory and hippocampal volume: a pilot-study in tree shrews. Psychoneuroendocrinology 2000;25:357-63.
15. Spiegel RJ, Vigersky RA, Oliff AI, et al. Adrenal suppression after short-term corticosteroid therapy. Lancet 1979;1:630-3.
16. Kuperman H, Damiani D, Chrousos GP, et al. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy. J Clin Endocrinol Metab 2001;86:2993-6.
17. van Rossum EF, Koper JW, Huizenga NA, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002;51:3128-34.
18. van Rossum EF, Koper JW, van den Beld AW, et al. Identification of the Bcl I polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo, and body mass index. Clin Endocrinol 2003;59:585-92.
19. Huizenga NA, Koper JW, De Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998;83:144-51.
20. Van Rossum EF, Lamberts SW. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 2004;59:333-57.
21. Rosmond R, Bouchard C, Bjorntorp P. Tsp509I polymorphism in exon 2 of the glucocorticoid receptor gene in relation to obesity and cortisol secretion: cohort study. BMJ 2001;322:652-3.
22. Dobson MG, Redfern CP, Unwin N, et al. The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus. J Clin Endocrinol Metab 2001;86:2270-4.
23. Di Blasio AM, van Rossum EF, Maestrini S, et al. The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin Endocrinol 2003;59:68-74.
24. Lin RCY, Wang WYS, Morris BJ. High penetrance, overweight, and glucocorticoid receptor variant: case-control study. BMJ 1999;319:1337-8.
25. Lin RC, Wang WY, Morris BJ. Association and linkage analyses of glucocorticoid receptor gene markers in essential hypertension. Hypertension 1999;34:1186-92.
26. Rosmond R, Chagnon YC, Holm G, et al. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes Res 2000;8:211-8.
27. Clement K, Philippi A, Jury C, et al. Candidate gene approach of familial morbid obesity: linkage analysis of the glucocorticoid receptor gene. Int J Obes Relat Metab Disord 1996;20:507-12.
28. Tissing WJE, Meijerink JPP, den Boer ML, et al. Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia. Clin Cancer Res 2005;11:6050-6.
29. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-22.
30. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000;14:2205-22.
31. Schrappe M, Stanulla M. Treatment of childhood acute lymphoblastic leukemia. In: Pui CH, editor. Current clinical oncology: treatment of acute leukemias: new directions for clinical research. Totowa (NJ): Humana Press Inc.; 2003.
32. Doerffel W, Luders H, Ruhl U, et al. Trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 2003;215:139-45.
33. Koerholz D, Claviez A, Hasenclever D, et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004;216:150-6.
34. Arbeitsgruppe Deutsche Child Behavior Checklist: Elternfragebogen ueber das Verhalten von Kindern und Jugendlichen; Deutsche Bearbeitung der Child Behavior Checklist (CBCL/4-18). Koeln, Arbeitsgruppe KJFD; 1998.
35. Mick E, Biederman J, Pandina G, et al. A preliminary meta-analysis of the child behavior checklist in pediatric bipolar disorder. Biol Psychiatry 2003;53:1021-7.
36. Lemstra AW, van Meegen MT, Vreyling JP, et al. 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology 2001;55:514-6.
37. Wakabayashi H, Yano M, Tachikawa N, et al. Increased concentrations of 14-3-3ε, γ and ζ isoforms in cerebrospinal fluid of AIDS patients with neuronal destruction. Clin Chim Acta 2001;312:97-105.
38. Hsich G, Kenney K, Gibbs CJ, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-30.
39. Irani DN, Kerr DA.14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis. Lancet 2000;355:901.
40. Hochhauser CJ, Lewis M, Kamen BA, et al. Steroid-induced alterations of mood and behavior in children during treatment for acute lymphoblastic leukemia. Support Care Cancer 2005;13:967-74.
41. Martinez-Yelamos A, Saiz A, Sanchez-Valle R, et al. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology 2001;57:722-4.
42. Holsboer F, Lauer CJ, Schreiber W, et al. Altered hypothalamic-pituitary- adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995;62:340-7.
43. Plotsky PM, Owens MJ, Nemeroff CB. Psychoneuroendocrinology of depression. Hypothalamicpituitary-adrenal axis. Psychiatr Clin North Am 1998;21:293-307.
44. Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000;255:542-5.
45. Felner EI, Thompson MT, Ratliff AF, et al. Time course of recovery of adrenal function in children treated for leukemia. J Pediatr 2000;137:21-4.
46. Schlaghecke R, Kornely E, Santen RT, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992;326:226-30.
47. Petersen KB, Müller J, Rasmussen M, et al. Impaired adrenal function after glucocorticoid therapy in children with acute lymphoblastic leukemia. Med Pediatr Oncol 2003;41:110-4.
48. Rix M, Birkebaek NH, Rosthoj S, et al. Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: a prospective observational study using the low-dose adrenocorticotropin test. J Pediatr 2005;147:645-50.
49. Rai R, Cohen J, Venkatesh B. Assessment of adrenocortical function in the critically ill. Crit Care Resusc 2004;6:123-9.